| Literature DB >> 35407706 |
Palak Jethva1, Munira Momin2, Tabassum Khan3, Abdelwahab Omri4.
Abstract
Upconverting luminescent nanoparticles (UCNPs) are "new generation fluorophores" with an evolving landscape of applications in diverse industries, especially life sciences and healthcare. The anti-Stokes emission accompanied by long luminescence lifetimes, multiple absorptions, emission bands, and good photostability, enables background-free and multiplexed detection in deep tissues for enhanced imaging contrast. Their properties such as high color purity, high resistance to photobleaching, less photodamage to biological samples, attractive physical and chemical stability, and low toxicity are affected by the chemical composition; nanoparticle crystal structure, size, shape and the route; reagents; and procedure used in their synthesis. A wide range of hosts and lanthanide ion (Ln3+) types have been used to control the luminescent properties of nanosystems. By modification of these properties, the performance of UCNPs can be designed for anticipated end-use applications such as photodynamic therapy (PDT), high-resolution displays, bioimaging, biosensors, and drug delivery. The application landscape of inorganic nanomaterials in biological environments can be expanded by bridging the gap between nanoparticles and biomolecules via surface modifications and appropriate functionalization. This review highlights the synthesis, surface modification, and biomedical applications of UCNPs, such as bioimaging and drug delivery, and presents the scope and future perspective on Ln-doped UCNPs in biomedical applications.Entities:
Keywords: bioimaging; biosensors; lanthanides; luminescence; upconversion nanoparticles
Year: 2022 PMID: 35407706 PMCID: PMC8999924 DOI: 10.3390/ma15072374
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Synthesis, properties, and applications of UCNPs.
Figure 2Structure of core–shell upconversion nanoparticle.
Figure 3Components of UCNPs and mechanism of energy transfer in UCNPs.
Figure 4Synthesis of α-NaYF4: Yb3+/Tm3+ or α-NaYF4: Yb3+/Er3+ UCNPs via thermal decomposition method.
Methods for synthesis of UCNPs.
| Methods | Conditions | Advantages | Disadvantages | Examples | References |
|---|---|---|---|---|---|
| Thermal decomposition | Higher temperature with an anhydrous anaerobic environment | High uniformity and monodisperse crystals, high luminous efficiency | Expensive, toxic byproducts are formed | NaYF4, NaYbF4, LiYF4 | [ |
| Co-precipitation method | Soluble salt solution, precipitant, coordinating ligand | Cost-effective with a simple operation process, ultrasmall UCNPs can be formed, usually requiring post treatment | Lack of particle size control | NaGdF4, LaF3, | [ |
| Hydrothermal method | Higher temperature and pressure conditions | Simple and inexpensive, good control of morphology and the size of crystals can control the shape and size of the product | Nanocrystal growth process cannot be observed | NaYF4, NaYbF4, YVO4, BaYF2 | [ |
| Microemulsion method | Appropriate surfactant to stabilize a micelle and/or to control the growth of nanocrystals | Simple operation process, narrow size, high stability | In most cases, calcination or annealing is usually required | LaF3, NaYF4 | [ |
| Combustion method | Explosive reaction by heating, the reaction temperature is generally 500–3000 °C | Faster reaction time and less utilization of energy; controllable product quantity | Poor product purity and luminescence | Ba5(PO4)3OH: Er3+/Yb3+ | [ |
| Sol-gel processing method | High luminescence intensity due to high crystallinity at high annealing temperature | Inexpensive precursors; small product size and simple procedures | Broad particle size and unsuitable for bioapplication | GdVO4 | [ |
Figure 5Surface modification of UCNPs for modulating its properties.
Figure 6Development of UCNPs in imaging modalities.
Composition and synthesis of UCNPs for bioimaging application.
| Composition/Modifier | Results | Route of Synthesis | References |
|---|---|---|---|
| β-NaY/GdF4: Yb, Er, Tm (UCNP) | Targets the lymphatic node, used for MR and CT imaging | Thermal decomposition | [ |
| NaYF4:Yb3+, Er3+ | In vitro and in vivo fluorescence results demonstrated the potency of tumor cell killing and significant suppression of tumor growth without any detectable side effects | Hydrothermal method | [ |
| NaYF4:5%Nd@NaGdF4/DSPE-PEG2000 | Strongest photoluminescence among the resultant NCs for NIR-II fluorescence imaging, and possess strong paramagnetism and X-ray attenuation for MRI and CT imaging | Liquid–solid-solution | [ |
| NaLuF4:Gd3+/Yb3+/Tm3+/Oleic acid | Used for fluorescence imaging/MRI | Solvothermal method | [ |
| NaYbF4:Tm3+/PEG | CT and strong NIR-fluorescent imaging that demonstrates both high in vitro and in vivo performances in the dual-bioimaging; very low cytotoxicity | User-friendly method [ | [ |
| NaYF4: Yb, Er@NaYF4: Yb, Nd UCNPs /Folate–chitosan | Effective UCL/CT imaging and combined chemotherapy and photothermal therapy | - | [ |
Figure 7Mechanism of FRET resulting in fluorescence.
UCNPs used in biosensing.
| Mechanism | Biomarker | Probes | Limit of | Applications | Reference |
|---|---|---|---|---|---|
| Fluorescence | CaF2:RE3+@MSN+ Fe3O4 | Oligonucleotide | 100 nM | Multiple breast cancer-related miRNA biomarkers. | [ |
| Fluorescence | Dipicolinic acid (DPA) | UCNPs−TPP/EBT | 0.9 μM | Analysis of DPA in human serum. | [ |
| Luminescence resonance energy transfer | Fe3+ | NaYF4:Yb,Er,Tm@NaGdF4/ Nile red derivative (NRD) fluorescent | 106.2 nM | Development of mPEG-UCNPs-NRD nanostructure used for detecting the intracellular Fe3+. | [ |
| Fluorescence resonance energy transfer | Microrna-122 | NaGdF4@NaGdF4: Yb,Er@DNA | 10−13 M | Sandwich-hybridization observed between miR-122 and the designed DNAs. | [ |
| Photoelectrochemical (PEC) aptasensing | Carcinoembryonic antigen | NaYF4:Yb, Tm@TiO2 upconversion microrods | 3.6 pg/mL | NIR light-mediated PEC aptasensing system exhibiting a PEC response towards target CEA and its detection. | [ |
| Fluorescence | Cyt c aptamer | NaYF4:Yb,Er@ | 20 nM | Intracellular Cyt c evaluation using UCNP@PDA@AP. | [ |
| Luminescence resonance energy transfer | Carbohydrate antigen125 (CA125) | Polyacrylic acid (PAA)-coated UCNPs | 9.0 × 10−3 U/mL−1 | CA125 quantification in human serum, construction of point-of-care testing (POCT) devices. | [ |
| Fluorescence | Prostate-specific antigen (PSA) | Anti-PSA antibodies | 0.01 ng/mL | Biochip sensor for early diagnosis of cancer markers. | [ |
Figure 8UCNP and DOX were loaded into gel nanoparticles and modified with PEI and DMMA to construct a nanolongan schematic with multiple transformations and corresponding anticancer mechanisms.
UCNPs in drug delivery.
| Material | Payload Drug in UCNPs | UCL Excitation (nm) | Therapeutic | Release Profile | Results | References |
|---|---|---|---|---|---|---|
| UCNPs@PDL | DOX | 980 nm | - | - | Nanotheranostic agent developed to achieve highly localized therapy with great therapeutic efficacy against malignant tumors | [ |
| NaYF4:Yb3+, Tm3+ | DOX | 980 nm | - | Increase in DOX release by activation of NIR light | Development of NIR light-triggered drug release of encapsulated DOX molecules by using UCNP/polymer nanomaterials in diblock copolymer self-assembly | [ |
| UCNPs@MIL-PEG | DOX | 980 nm | Therapeutic efficacy-60% | Less than 20% at pH = 7.4 | Application of multifunctional UCNPs@MIL-PEG nanoparticles for UCL/MR dual-mode imaging and pH-responsive anticancer drug delivery | [ |
| NaYF4: Tm3+, Yb3+ | Nile Red | 980 nm | - | - | Synthesized hybrid nanoparticles release the Nile red in response to a NIR-triggered drug release stimulus | [ |
| NaYF4: Yb,Er/PAA/PEI nanoparticles | MDR1-siRNA | 980 nm | Drug loading rate: 34.1% | 50% MDR1-siRNA released from UCNP/PAA/PEI/MDR1-siRNA complex | UCNP nano complex—effective in gene silencing in paclitaxel-resistant ovarian cancer cells and resensitizes them to paclitaxel treatment | [ |
| UCNPs@SiO2@PNBAM/MAA | DOX | 980 nm | Drug loading rate: 7.23 wt% | Release rate constants and the correlation coefficients 4.15 × 10−6 and 0.98 (pH 7.4 and visible light), 2.64 × 10−5 and 0.99 (NIR light), 3.26 × 10−5 and 0.97 (pH 4.5 and visible light), 2.59 × 10−4 and 0.99 (pH 4.5 and NIR light), respectively | NIR irradiation and acidic conditions are beneficial to drug release; this controlled release feature makes the nanocomposite a promising carrier of drugs | [ |
| NaYF4:Er/Yb@NaGdF4 ePEG | DOX | 980 nm | - | - | Nuclear-targeted UCNPs-based theranostic systems combined with MR/optical imaging for cell nuclei and direct nuclear drug delivery functionalities to deliver drugs into the cell nuclei more efficiently | [ |
| NaYF4:Yb/Tm/Er | hydrophobic AB3 | 980 nm | Loading efficiency: 16.7 wt% | Released without the 980 nm laser (<14 wt%) after 16 h. With a 10 min irradiation of 980 nm laser—nearly 75 wt% of drugs released after 16 h | A superior chemotherapy efficacy, whereas in vivo studies demonstrated that AB3-loaded UCNP-based micelles capable of targeted combination chemotherapy and PDT—provides a better antitumor efficacy compared to chemotherapy or PDT alone, without any apparent systemic toxicity | [ |
Figure 9Type I and Type II reactions in PDT (photodynamic therapy).